Portola Pharmaceuticals (PTLA) Receiving Somewhat Positive Press Coverage, Analysis Finds
Headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.9656181722566 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- Portola Pharmaceuticals (PTLA) Rating Lowered to Strong Sell at BidaskClub (americanbankingnews.com)
- Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) – GlobeNewswire (press release) (globenewswire.com)
- The Stock on Analysts Watch-List: Portola Pharmaceuticals, Inc. (PTLA) – Wall Street Morning (wallstreetmorning.com)
- Portola Pharmaceuticals: Does This 2017 Winner Still Have ROTY Potential? – Seeking Alpha (seekingalpha.com)
- Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) – Nasdaq (nasdaq.com)
PTLA has been the topic of a number of analyst reports. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 target price on the stock. Oppenheimer reaffirmed a “buy” rating and set a $80.00 target price on shares of Portola Pharmaceuticals in a research note on Tuesday, November 7th. Credit Suisse Group set a $70.00 target price on Portola Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 10th. They noted that the move was a valuation call. BidaskClub raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $71.15.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $4.71 million. During the same quarter in the prior year, the firm posted ($1.64) earnings per share. The company’s quarterly revenue was down 58.9% on a year-over-year basis. equities analysts predict that Portola Pharmaceuticals will post -4.95 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Portola Pharmaceuticals (PTLA) Receiving Somewhat Positive Press Coverage, Analysis Finds” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/08/portola-pharmaceuticals-ptla-receiving-somewhat-positive-press-coverage-analysis-finds.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Stock Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.